IL6 and rheumatoid arthritis: 2-DG, a non-competitive inhibitor of HKs, reverses LPS-induced enhancement of glycolytic activity and inhibits the expression of vital inflammatory cytokines (IL1-β, IL6) and matrix metalloproteinases (MMP-1, MMP-3) in the RA pathogenesis (75).